Apollo Hospitals faces a new margin risk

Apollo Hospitals Enterprise Limited (APOLLOHOSP) fell about 6% after the Supreme Court questioned steep mark-ups on medicines sold through hospitals. The court highlighted a case where a cancer drug costing about ₹2,700 was sold for nearly ₹27,000. This matters because pharmacy is an important part of hospital economics. Any future rule that limits medicine mark-ups could reduce revenue and margins for hospital operators. But the current discussion is not a new regulation yet. The Supreme Court has raised concerns and asked the government to examine the issue. The financial impact on Apollo therefore cannot be calculated precisely at this stage. My view is that the stock reaction is pricing in a risk that is still uncertain. Apollo's Q1 FY27 numbers were strong. Revenue grew 20.6% to ₹7,044 crore and EBITDA increased 28% to ₹1,092 crore. EBITDA margin improved from 14.6% to 15.5%. What I am watching now is the scope of any eventual regulation. A rule covering only selected medicines would have a different impact from a broad cap across hospital pharmacy sales. The next clear trigger is the Supreme Court hearing on October 12. My stance: I would not treat the current fall as either a confirmed earnings hit or a buying signal. I want regulatory clarity first. A broad pricing restriction would make me more cautious. Limited regulation would change that view. I do not hold Apollo Hospitals Enterprise Limited at the time of writing.